Search company, investor...

Mountain Crest Acquisition II

Founded Year

2021

Stage

IPO | Merged

Valuation

$0000 

About Mountain Crest Acquisition II

Mountain Crest Acquisition II (NASDAQ: MCADU) is a blank check company, also commonly referred to as a Special Purpose Acquisition Company, or SPAC, formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities.

Headquarters Location

311 W 43rd St 12th Fl

New York, New York, 10036,

United States

646-493-6558

Missing: Mountain Crest Acquisition II's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Mountain Crest Acquisition II's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Latest Mountain Crest Acquisition II News

Digital health firm Better Therapeutics makes Nasdaq debut

Nov 1, 2021

November 1, 2021 Better Therapeutics has joined the ranks of publicly-listed digital health companies after completing a merger with blank cheque company Mountain Crest Acquisition Corp II. The company, which specialises in prescription digital therapeutics (DTx) for cardiometabolic diseases, listed on the Nasdaq under the BTTX ticker late on Friday. Shares initially fell back slightly from an opening price of $10.04 after the merger closed with the special purchase acquisition company (SPAC), but then rocketed to $16.76 in pre-market trading. The SPAC route to a public listing is increasingly being used by digital health companies as an alternative to an initial public offering (IPO), with other recent examples including DTx specialist Pear Therapeutics and telehealth company Babylon Health. It can be quicker, simpler and cheaper than an IPO, which can see investment banks taking a sizeable slice of gross proceeds in fees, but also involves less scrutiny of a company’s finances, liabilities and operational processes. The proceeds of around $70 million will keep the company funded through 2023, and will be used to bring forward Better Therapeutics’ lead prescription DTx for type 2 diabetes – BT-001 – through clinical trials and submission for FDA approval, according to the digital health company. BT-001 is a tool designed to change behaviours that are the root cause of type 2 diabetes, and is being investigated in a pivotal study as a treatment used under physician supervision for people with uncontrolled diabetes. The DTx works by blending clinical, behavioural and psychological inputs into a series of therapy lessons and skill-building modules. Better Therapeutics recently recruited the first patient in a real-world study of BT-001 partnered with US primary care organisation Catalyst Health Network to gauge the long-term impact of the tool. The cash injection will also be used to advance the digital health firm’s prescription DTx pipeline for other cardiometabolic conditions, which includes BT-002 for hypertension and BT-003 for high blood cholesterol as well as a candidate for non-alcoholic fatty liver disease (NAFLD). Better Therapeutics meanwhile also gets access to an additional $40 million credit facility, subject to certain milestones being achieved. “We envision a future where digital therapeutics are often the first prescription written in order to address the root causes of disease caused by patient behaviours,” said Kevin Appelbaum, Better Therapeutics’ co-founder and chief executive “The completion of this transaction and the capital raised will be instrumental in helping our team lead the way in this transformation, beginning with cardiometabolic diseases,” he added. Don't miss your daily pharmaphorum news.

Mountain Crest Acquisition II Frequently Asked Questions (FAQ)

  • When was Mountain Crest Acquisition II founded?

    Mountain Crest Acquisition II was founded in 2021.

  • Where is Mountain Crest Acquisition II's headquarters?

    Mountain Crest Acquisition II's headquarters is located at 311 W 43rd St, New York.

  • What is Mountain Crest Acquisition II's latest funding round?

    Mountain Crest Acquisition II's latest funding round is IPO.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.